000177233 001__ 177233
000177233 005__ 20240229133734.0
000177233 0247_ $$2doi$$a10.1016/j.ijrobp.2021.07.160
000177233 0247_ $$2pmid$$apmid:34700599
000177233 0247_ $$2ISSN$$a0360-3016
000177233 0247_ $$2ISSN$$a1879-355X
000177233 0247_ $$2altmetric$$aaltmetric:115847982
000177233 037__ $$aDKFZ-2021-02367
000177233 041__ $$aEnglish
000177233 082__ $$a610
000177233 1001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b0$$eFirst author$$udkfz
000177233 245__ $$aDevelopment of a Hypoxia-Immune Prognostic Classifier for Head-and-Neck Cancer Patients Undergoing Radiotherapy - Results From a Prospective Imaging Trial.
000177233 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2021
000177233 3367_ $$2DRIVER$$aarticle
000177233 3367_ $$2DataCite$$aOutput Types/Journal article
000177233 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1675085389_23510
000177233 3367_ $$2BibTeX$$aARTICLE
000177233 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177233 3367_ $$00$$2EndNote$$aJournal Article
000177233 500__ $$a#EA:E050#
000177233 520__ $$aTumor-infiltrating lymphocytes (TILs) correlate with an improved outcome of head-and-neck squamous cell cancer (HNSCC) patients undergoing radiotherapy and are influenced by the tumor microenvironment and tumor-associated hypoxia. The present analysis is based on a prospective imaging trial and analyzes the value of TILs and tumor-associated hypoxia to stratify HNSCC patients according to their response to radiotherapy.A total of 49 patients with locoregionally advanced HNSCCs were prospectively enrolled in this trial and underwent longitudinal hypoxia PET imaging using fluoro-18 misonidazole ([18F]FMISO) in weeks 0, 2 and 5 during chemoradiation. Tumor hypoxia was assumed for a tumor-to-background SUV (contralateral sternocleidomastoid muscle) exceeding 1.4, and an early hypoxia response was defined as a decrease in the normalized maximum intratumoral SUV (FMISO-SUVindex) between weeks 0 and 2. Pre-treatment tumor biopsies were analyzed for TILs and the hypoxia tissue marker carbonic anhydrase IX (CAIX). Trial patients were stratified into 4 subgroups based on their TIL numbers (> 100 vs. < 100 TILs/HPF) and expression of CAIX (above vs. below median H-score), and locoregional control (LRC) and progression-free survival (PFS) rates for all subgroups were assessed using Cox and subsequent concordance analyses (Harrell's C).High TIL levels correlated with improved LRC (HR = 0.279, P = 0.011) and PFS (HR = 0.276, P = 0.006). Similarly, a decrease in the FMISO-SUVindex within the first 2 weeks of treatment corresponded with better LRC (HR = 0.321, P = 0.015) and PFS (HR = 0.402, P = 0.043). Harrell's C was 0.68, when TILs and early hypoxia PET response were combined. The hypoxia PET-based hypoxia-immune classifier separated 3 distinct prognostic patient subgroups, a favorable (TILhigh/ early PET response), and intermediate (TILhigh/no early PET response or TILlow/early PET response) and a poor (TILlow/no early PET response) prognostic group with 2-year LRC of 71%, 33% and 0%, respectively. Low pre-treatment tissue levels of CAIX were also prognostic for improved LRC (HR = 0.352, P = 0.050) but not PFS (HR = 0,468, P = 0,087). Harrell's C was 0.66 for CAIX and TILs separately and 0.71 for the combination. The immunohistochemistry-based immune-hypoxia classifier similarly stratified between a favorable (CAIXlow/TILhigh), an intermediate (CAIXlow/TILlow or CAIXhigh/TILhigh) and a poor (CAIXhigh/TILlow) subgroup with 2-year LRC rates of 73%, 62% and 11%, respectively.We developed a hypoxia PET-based hypoxia-immune classifier that was able to separate HNSCC patients into 3 distinct prognostic subgroups based on their tumor biology. These subgroups could also be stratified in a clinically feasible, immunohistochemistry-based classifier with comparable model accuracy. Therefore, this hypoxia-immune classifier could help to stratify prognoses of HNSCC patients undergoing radiotherapy pending validation in an external cohort.
000177233 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000177233 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177233 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, A.$$b1$$udkfz
000177233 7001_ $$aMix, M.$$b2
000177233 7001_ $$0P:(DE-HGF)0$$aWiedenmann, N.$$b3
000177233 7001_ $$0P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aStoian, R. G.$$b4$$udkfz
000177233 7001_ $$0P:(DE-HGF)0$$aNiedermann, G.$$b5
000177233 7001_ $$0P:(DE-HGF)0$$aBaltas, D.$$b6
000177233 7001_ $$0P:(DE-He78)ad0ed5484fb008b6597171a8a348b26f$$aWerner, M.$$b7$$udkfz
000177233 7001_ $$0P:(DE-He78)b4d6f1a97e32c14ff3857fd0c8eda6be$$aRuf, Benjamin$$b8
000177233 7001_ $$0P:(DE-HGF)0$$aKayser, G.$$b9
000177233 7001_ $$0P:(DE-HGF)0$$aGrosu, A.$$b10
000177233 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2021.07.160$$gVol. 111, no. 3S, p. S63 - S64$$n3S$$pS63 - S64$$tInternational journal of radiation oncology, biology, physics$$v111$$x0360-3016$$y2021
000177233 909CO $$ooai:inrepo02.dkfz.de:177233$$pVDB
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)75b4c256a6de824414938cf2aaeff88e$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ad0ed5484fb008b6597171a8a348b26f$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b4d6f1a97e32c14ff3857fd0c8eda6be$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000177233 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000177233 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000177233 9141_ $$y2021
000177233 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-27$$wger
000177233 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2019$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-01-27
000177233 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2019$$d2021-01-27
000177233 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x0
000177233 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Molekulare Radioonkologie$$x1
000177233 980__ $$ajournal
000177233 980__ $$aVDB
000177233 980__ $$aI:(DE-He78)FR01-20160331
000177233 980__ $$aI:(DE-He78)E055-20160331
000177233 980__ $$aUNRESTRICTED